BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, July 20, 2025
See today's BioWorld
Home
» Opna Bio recasts mental retardation protein as cancer immunotherapy target
To read the full story,
subscribe
or
sign in
.
Newco news
Opna Bio recasts mental retardation protein as cancer immunotherapy target
Nov. 22, 2022
By
Anette Breindl
Swiss-American startup Opna Bio SA launched this week with a $38 million series A, a
Science
paper on one of its targets and a pipeline stretching from preclinical to phase II.
BioWorld
Newco news
Cancer
Series A